cisplatin

Cisplatin is a "first generation" antitumor drug highly effective in the chemotherapy of many forms of cancer. Thge metallodrug is most commonly used to treat testicular, bladder, lung, gullet (oesophagus), stomach and ovarian cancers. The water-soluble platinum complex, after hydrolysis, reacts with the nucleic acid bases of DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
 
IUPAC name: cis-diamminedichloroplatinum(II).



The term "cisplatin" was found in the following pages:

Link database: Cisplatin, Carboplatin, and Oxaliplatin Interactions With Plasma Proteins
Side effects of cisplatin chemotherpy: Platinum speciation matters | EVISA's News
Link database: Austria: University of Vienna: Institute of Inorganic Chemistry: Working group of B. Keppler
Link database: Lipoplatin -
Link database: Australia: University of Western Sydney: Biologically Active Drugs by Design Group
Link database: DrugBank: Cisplatin
Link database: National Cancer Institute: Cisplatin
Scientific publications with participation of EVISA | EVISA's News
„Forever young“ oder wirklich jung? - Metallomics im Fokus der Biochemie | EVISA's News
Speciation and Toxicity | EVISA's News
Copper molecule shows promise in fighting against cancer | EVISA's News
Link database: Cisplatin: Cancerbackup
Link database: Speciation, bioavailability and antigenotoxicity of Selenium species present in Selenium enriched natural products.
Metallomics 2011: Chemiker der Universität Münster laden zu Symposium über die Rolle von Metallen in Biologie und Medizin ein | EVISA's News
Brief summary: Speciation analysis for the study of metallodrugs and their biomolecular interactions | EVISA's News
Link database: Chemocare: Cisplatin
Link database: ChemCases: Cisplatin: The Invention of an Anticancer Drug
A new quantification strategy for bioimaging by laser ablation - inductively coupled plasma-mass spectrometry based on isotope dilution analysis | EVISA's News
Link database: DrugBank: Oxaliplatin
Nanoscale Metal-Organic Frameworks (NMOFs): A new way to create better MRI Contrast Agents | EVISA's News